PHA-793887

• Description:

  PHA-793887 is a potent, ATP-competitive CDK inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC50s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC50 of 79 nM.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/PHA-793887.html

• Purity:

  99.25

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  CC (C) CC (NC1=NNC2=C1CN (C (C3CCN (C) CC3) =O) C2 (C) C) =O

• Molecular Formula:

  C19H31N5O2

• Molecular Weight:

  361.48

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Locatelli G, et al. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol Cancer Ther. 2010 May;9 (5) :1265-73.|[2]Massard C, et al. A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 2011 Mar 15;10 (6) :963-70. Epub 2011 Mar 15.|[3]Alzani R, et al. Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Exp Hematol. 2010 Apr;38 (4) :259-269.e2.|[4]Brasca MG, et al. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem. 2010 Mar 1;18 (5) :1844-53.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  CDK1; CDK2; CDK4; CDK5; CDK7; CDK9

• CAS Number:

  718630-59-2